Home›Stock Screener›Bafna Pharmaceuticals

Bafna Pharmaceuticals Share Price Today | Stock Price & Bafna Pharmaceuticals Share Screener

BAFNAPH Pharmaceuticals & Biotechnology
Live Share Price NSE
₹193.97
▲ 17.63 (10.00%)
2026-06-08 00:00:00
Live Share Price BSE
₹479.80
▲ 2.80 (0.59%)
2026-11-19 00:00:00

As of June 8, 2026, the live Bafna Pharmaceuticals share price (NSE: BAFNAPH) is ₹193.97 on NSE and ₹479.80 on BSE, up 10.00% from the previous close, with shares trading between ₹187.35 and ₹193.97 in today's trading session, and a 52-week range of ₹99.16–₹193.97. Track Bafna Pharmaceuticals marketcap in USD to gauge the company's total market size. Use the Bafna Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Bafna Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹7 and net income of ₹-2, with EBITDA of ₹-3, an operating margin of -42.0% and a profit margin of -28.6%.

Bafna Pharmaceuticals Market Cap ₹1,118.94 Cr.
BAFNAPH P/E Ratio (TTM) 99.40
Bafna Pharmaceuticals P/B Ratio 11.10
EPS (TTM) ₹-15.52
Dividend Yield -
Debt to Equity 0.70
BAFNAPH 52 Week High ₹193.97
Bafna Pharmaceuticals 52 Week Low ₹99.16
Operating Margin -42.00%
Profit Margin -28.57%
BAFNAPH Revenue (TTM) ₹7.00
EBITDA ₹-3.00
Net Income ₹-2.00
Total Assets ₹71.00
Total Equity ₹51.00

Bafna Pharmaceuticals Share Price Chart

Track the current stock price of Bafna Pharmaceuticals with an interactive chart. Analyse BAFNAPH share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Bafna Pharmaceuticals stock quote in one place.

The quote of ₹193.97 sits between the 52-week low of ₹99.16 and the 52-week high of ₹193.97, and the latest session moved 10.00% from the previous close.

Bafna Pharmaceuticals Company Profile - Fundamental Screener

Screen Bafna Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BAFNAPH shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE878I01022.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE878I01022

Bafna Pharmaceuticals Balance Sheet Screener

Screen BAFNAPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2020, total assets were ₹71, down from ₹120 in 2019.

Latest statistics put total assets at ₹71 and shareholder funds at ₹51, with a leverage ratio of 0.70.

Item 2020 2019 2018 2017 2016 2015

Assets

Total Assets 71 120 138 178 193 200
Current Assets 0 0 0 0 0 0
Fixed Assets 35 37 45 49 53 55

Liabilities

Total Liabilities 0 0 0 0 0 0
Current Liabilities 3 30 41 55 40 16
Non-Current Liabilities 0 0 0 0 0 0

Shareholders' Equity

Total Equity 51 19 37 42 58 73
Share Capital 2 24 24 19 19 19
Reserves & Surplus -7 -5 14 20 39 53

Bafna Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Bafna Pharmaceuticals income statement and profit fundamentals. Analyze BAFNAPH quarterly results. Bafna Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2019-Jun, revenue was ₹7 and net profit was ₹-2, equal to earnings per unit of ₹-0.90, at an operating margin of -42%.

In that period expenses were ₹10, interest cost ₹0 and tax ₹-2. The next period listed, 2019-Sept, shows revenue of ₹12 and net profit of ₹-1.

Item 2019-Jun 2019-Sept 2018-Jun 2018-Sept

Revenue and Expenses

Revenue 7 12 12 9
Expenses 10 12 14 9

Operating Costs and Margins

EBITDA -3 0 -2 0
Operating Profit % -42.00% -3.00% -15.00% 2.00%
Depreciation 1 1 1 1
Interest 0 0 1 1

Profit and Earnings

Profit Before Tax -4 -1 -4 -1
Tax -2 0 0 0
Net Profit -2 -1 -4 -1
EPS -0.90 -0.25 0.00 -0.80

Bafna Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen BAFNAPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2020-March, operating activities used ₹34, and net cash flow was an inflow of ₹6.

Over the same period, investing activities provided ₹33 and financing activities provided ₹7.

Item 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Cash from Operations and Investing

Operating Activities -34 -2 -7 -1 1 11
Investing Activities 33 15 38 -5 0 60

Financing and Net Cash

Financing Activities 7 -14 -31 6 -1 -71
Net Cash Flow 6 0 0 0 0 0

Bafna Pharmaceuticals Shareholding Pattern Screener

See Bafna Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Bafna Pharmaceuticals promoter holding and ownership changes for BAFNAPH on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 75.00%, foreign institutions 9.34%, domestic institutions 0.00% and the public 12.13%, spread across 6,928 shareholders.

The shareholder count was 6,928 in 2026-Mar, compared with 7,062 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 88.30%

Institutional Investors

FII Holding 9.34% 9.34% 9.34% 8.53% 9.34% 9.34% 9.34% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 12.13% 11.97% 11.97% 11.06% 11.62% 12.03% 12.13% 7.48%
Other Holding 3.53% 3.69% 3.69% 5.40% 4.04% 3.63% 3.53% 4.23%
Shareholder Count 6,928 7,062 6,810 7,142 7,283 7,572 7,119 7,539

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Bafna Pharmaceuticals. Bafna Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Bafna Pharmaceuticals.

Bafna Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Bafna Pharmaceuticals stock. Check BAFNAPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Bafna Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Bafna Pharmaceuticals Market Events Screener - Corporate Actions

Get Bafna Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Bafna Pharmaceuticals stock events that may affect BAFNAPH share price, along with derivatives, futures and options activity and sector gainers.

12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 11, 2026, with a record date of November 11, 2026.

It is followed by Annual General Meeting dated September 11, 2026 and Quarterly Result Announcement dated August 11, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-11 2026-11-11 Quarterly Result Announcement NA 5.04%
2026-09-11 2026-09-11 Annual General Meeting NA 4.47%
2026-08-11 2026-08-11 Quarterly Result Announcement NA 2.08%
2026-05-29 2026-05-29 Quarterly Result Announcement NA -2.79%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 6.76%
2025-11-11 2025-11-11 Quarterly Result Announcement NA 12.98%
2025-09-19 2025-09-19 Annual General Meeting NA 43.07%
2025-08-12 2025-08-12 Quarterly Result Announcement NA 10.01%
2025-05-26 2025-05-26 Quarterly Result Announcement NA -5.05%
2025-02-06 2025-02-06 Quarterly Result Announcement NA 0.76%
2024-11-11 2024-11-11 Quarterly Result Announcement NA 2.21%
2024-09-25 2024-09-25 Annual General Meeting NA -2.66%

Bafna Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen BAFNAPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

Bafna Pharmaceuticals Company Announcements - News & Reports Screener

Screen BAFNAPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated November 15, 2026 and November 15, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-15 Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026 -
2026-11-15 Board Meeting Outcome for The Board Meeting Held On 11/11/2026 -
2026-11-10 Board Meeting Intimation for Meeting Scheduled On November 11 2026 -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-26 Closure of Trading Window -
2026-09-11 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-11 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-21 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-19 Notice Of 31St Annual General Meeting Of The Company For The F.Y 2025-2026 -
2026-08-19 Reg. 34 (1) Annual Report. -
2026-08-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-13 Book Closure For 31St Annual General Meeting -
2026-08-13 Shareholder Meeting - 31St AGM On September 11 2026 -
2026-08-11 Unaudited Financial Results For The Quarter Ended June 30 2026 -
2026-08-11 Board Meeting Outcome for The Board Meeting Held On 11/08/2026 -
2026-08-05 Board Meeting Intimation for Meeting Scheduled On August 11 2026 -
2026-07-09 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-06-26 Closure of Trading Window -
2026-06-22 Announcement under Regulation 30 (LODR)-Change in Directorate -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹193.97, within a 52-week range of ₹99.16 to ₹193.97. The P/E ratio is 99.40 and the P/B ratio is 11.10, with earnings per unit of ₹-15.52. Market capitalisation stands at ₹1,118.94 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 6 balance sheet periods, 4 income statement periods, 6 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.